Home > Pulmonology > ERS 2022 > Durable effect of endobronchial valves in severe emphysema

Durable effect of endobronchial valves in severe emphysema

Presented By
Prof. Gerard Criner, Temple University, PA, USA
Conference
ERS 2022
Trial
EMPROVE
The randomised-controlled EMPROVE trial demonstrated long-term added clinical benefits of bronchoscopic placement of endobronchial one-way valves with the SpirationĀ® Valve System (SVS) over medical management alone in treating hyperinflation in patients with severe heterogenous emphysema. Minimally invasive, bronchoscopic placement of endobronchial one-way valves have demonstrated to improve pulmonary function, reduce hyperinflation, and increase dyspnoea in patients with COPD and emphysema [1]. However, it is not established whether this treatment is superior to ā€˜no interventionā€™ in the long term. The EMPROVE trial (NCT01812447) randomised 174 patients with severe heterogenous emphysema 2:1 to active treatment with the SVS on top of medical management or to medical management alone. Assessed were several quality-of-life (QoL) endpoints to compare the 2 arms of the...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on